Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alli Return In U.S. Fattens Glaxo’s Consumer Outlook

This article was originally published in The Tan Sheet

Executive Summary

GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.

You may also be interested in...



Oxytrol For Women Exclusivity Ends Not With Competition, But Label Warning Change

Private labeler Perrigo has eyed launching a generic since FDA approved the 3.9mg oxybutynin transdermal as a first-in-class OTC in 2013. Currently, though, Perrigo says it is "not a big product" and is talking about other prescription OAB products that could be approved for OTC.

Glaxo/Novartis JV Wields ‘Power’ Brands, Switches To Spearhead Global Growth

Glaxo prioritizes seven “power” brands globally and also will invest in boosting sales of 12 “core” brands in its consumer JV with Novartis, says division head Emma Walmsley. The combination of the two firms’ consumer products puts the JV atop the OTC/wellness market in 36 countries.

Glaxo/Novartis JV Wields ‘Power’ Brands, Switches To Spearhead Global Growth

Glaxo prioritizes seven “power” brands globally and also will invest in boosting sales of 12 “core” brands in its consumer JV with Novartis, says division head Emma Walmsley. The combination of the two firms’ consumer products puts the JV atop the OTC/wellness market in 36 countries.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel